GlassScriptPhysician profile
Marie P Renoit
NPI 1932209814
$5,829.12
in general payments reported to CMS, 2019-2025
26 companies · $2,016 in 2025
The $2,016 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $520 · 2022: $837 · 2023: $1,000 · 2024: $1,457 · 2025: $2,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,472.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,345.45 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Merck Sharp & Dohme LLC | $490.72 | 2023-2025 | Winrevair, Verquvo |
| Actelion Pharmaceuticals US, INC. | $422.25 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Boston Scientific Corporation | $373.53 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $362.57 | 2023-2025 | Onpattro, Amvuttra |
| Pfizer INC. | $332.41 | 2021-2025 | |
| Scpharmaceuticals INC. | $325.40 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $315.89 | 2022-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $314.45 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $311.65 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.03 | 2022-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $195.21 | 2021-2024 | |
| Biotronik INC. | $153.00 | 2021 | |
| Impulse Dynamics (USA) INC. | $112.63 | 2023-2024 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.48 | 2021-2024 | Lifevest |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $78.38 | 2025 | Tyvaso |
| Bridgebio Pharma, INC. | $75.59 | 2025 | Attruby |
| Abbott Laboratories | $69.95 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Lexicon Pharmaceuticals, INC. | $58.71 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $34.94 | 2023-2024 | Xarelto |
| Ionis Pharmaceuticals, INC. | $22.48 | 2025 | Tryngolza |
| Kestra Medical Technology Services, INC. | $20.16 | 2024 | Assure Wcd |
| Endotronix, INC. | $20.00 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Sanofi-Aventis U.S. LLC | $19.74 | 2023 | |
| Chiesi USA, INC. | $18.52 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.98 | 2025 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Renoit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.